CSL Limited (ASX: CSL) Stock News Today: Buyback Update, Seqirus Uncertainty, and Analyst Forecasts for 2026

CSL Limited, the Melbourne‑based plasma and vaccines giant, is finishing 2025 under intense scrutiny from investors, regulators and politicians alike. As of the afternoon of 10 December 2025, CSL shares are trading around A$180–182, after closing at about A$181.82 on 9 December and slipping intraday today to roughly A$181.Intelligent Investor+1

CSL Limited’s share price has spent most of 2025 in the sin bin, but behind the drawdown sits a mix of solid earnings growth, a radical restructuring, a forthcoming spin‑off of its vaccines arm and fresh news today about a major new vaccine plant and an active on‑market buyback. Together, these developments are reshaping the investment story for one of the ASX’s most important healthcare names.

CSL Limited, long considered one of the ASX’s safest growth names, heads into Monday’s open on 24 November 2025 under a very different spotlight. A bruising year of profit downgrades, restructuring, and a sharp share price fall has collided with a fresh US$1.5 billion expansion plan in the United States and an active share buy-back.

CSL – Australia’s fourth-largest public company – stunned the market by cutting its profit outlook and delaying a major spinoff due to a steep and unexpected decline in flu vaccinations in the United States. In an AGM update on Oct. 28, the biotech revealed that U.S. influenza immunization rates are dropping far more than anticipated, undermining its Seqirus vaccine division’s performancereuters.com. CEO Paul McKenzie told shareholders that flu shot uptake in the U.S. was collapsing – a 12% decline in vaccination rates is now expected for the overall population this seasonmarketscreener.comreuters.com. “In our Seqirus business, we have seen a greater decline in influenza vaccination rates in the U.S. than we expected,” McKenzie said, with Chairman Brian McNamee calling the trend “remarkable”reuters.com. Policy shifts in Washington may be partly to blame – U.S. Health Secretary Robert F. Kennedy Jr. has taken a skeptical stance on vaccines, cutting funding for programs and even ousting the CDC chief who promoted flu shotsreuters.com. The unexpected vaccine slump, combined with a drop in demand for CSL’s plasma products in China, is hitting the company’s bottom linemarketscreener.com.

{“@context”:”https://schema.org”,”@type “:”LiveBlogPosting”,”@id”:”https://ts2.tech/en/stock-market-today-27-10-2025/#live”,”headline”:”Stock Market Today 27.10.2025″,”description”:”Live rolling coverage of technology news: AI, chips, gadgets, software, startups, cybersecurity, telecom, and policy.”,”datePublished”:”2025-10-27T06:00:02-04:00″,”dateModified”:”2025-10-28T00:00:03-04:00″,”coverageStartTime”:”2025-10-27T06:00:02-04:00″,”coverageEndTime”:”2025-10-28T00:00:03-04:00″,”author”:{“@type”:”Organization”,”name”:”TechStock²”},”publisher”:{“@type”:”Organization”,”name”:”TechStock²”,”logo”:{“@type”:”ImageObject”,”url”:”https://ts2.tech/wp-content/uploads/2024/02/cropped-ts2-logo-google.png”}},”inLanguage”:”en-US”,”liveBlogUpdate”:[{“@type”:”BlogPosting”,”@id”:”https://ts2.tech/en/stock-market-today-27-10-2025/#live/u/6a95e15f8ea8002e”,”headline”:”CSL faces second strike on executive pay as board survives spill vote”,”articleBody”:”CSL has recorded a second strike on its executive pay after more than 40% of votes opposed at its AGM in Melbourne. The approval threshold to trigger a board spill is 25%, so this marks a second consecutive rebuke, though shareholders voted to keep the current board. The biotech group has seen its share price slide this year, weighed by weaker US vaccination momentum and the costly 2022 acquisition of Swiss